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Abstract
In Alzheimer’s disease (AD), hallmark β-amyloid deposits are characterized by the pres-
ence of activated microglia around them. Despite an extensive characterization of the rela-
tion of amyloid plaques with microglia, little is known about the initiation of this interaction. In
this study, the detailed investigation of very small plaques in brain slices in AD transgenic
mice of the line APP-PS1(dE9) revealed different levels of microglia recruitment. Analysing
plaques with a diameter of up to 10 μmwe find that only the half are associated with clear
morphologically activated microglia. Utilizing in vivo imaging of new appearing amyloid pla-
ques in double-transgenic APP-PS1(dE9)xCX3CR1+/- mice further characterized the dy-
namic of morphological microglia activation. We observed no correlation of morphological
microglia activation and plaque volume or plaque lifetime. Taken together, our results dem-
onstrate a very prominent variation in size as well as in lifetime of new plaques relative to
the state of microglia reaction. These observations might question the existing view that am-
yloid deposits by themselves are sufficient to attract and activate microglia in vivo.
Introduction
Microglia activation is a characteristic feature of Alzheimer’s disease (AD). Although microglia
cells have been found to contact neurofibrillary tangles in the brain of Alzheimer’s patients
([1]), the association of microglia to amyloid plaques is a more frequent and distinguished
event ([2]; [3]). Plaques are extracellular proteinaceous aggregates mainly composed of the
β-amyloid peptide (Aβ). Proteolytically derived Aβmonomers successively aggregate into olig-
omeric species and thence amyloid fibrils, ultimately forming the pathognomonic amyloid
plaques which gradually grow in size ([4]). In the vicinity of amyloid plaques neurons are dam-
aged, as apparent by dystrophic neurites, the progressive loss of dendritic spines as well as the
loss of axons and neurons ([5]; [6]; [7]; [8]).
Microglia are the resident immune cells of the brain actively surveying the brain parenchy-
ma with their fine processes. After brain injury or immunological challenges, microglia are
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activated leading to the upregulated expression of immune-related molecules, including
interleukin-1 (IL-1) and transforming growth factor β ([9]; [10]). Once activated, microglia
prominently change their morphology: the ramified processes swell and withdraw, whilst their
cell bodies enlarge ([11]). In the AD brain, activation of microglia and clustering around amy-
loid deposits tend to occur early in the development of plaque pathology. Nevertheless, little is
known about the initiating event of this interaction. Here, we specifically focus on very small
newly-formed amyloid plaques and attempt to characterize the process by which microglia are
attracted to these lesions.
Material and Methods
Mice
Mouse lines APP-PS1(dE9) ([12]), CX3CR1-GFP ([13]) and YFP-H ([14]) were purchased
from The Jackson Laboratory, Bar Harbor, USA. Briefly, the transgenic APP-PS1 (dE9) mouse
line expresses human APP with Swedish mutation and mutant human Presinilin1 (PS1 delta
E9) both under the control of the mouse prion protein promoter resulting in abundant amyloid
plaques in cortex and hippocampus[12]. The knockin of gfp to the Cx3cr1 locus in CX3CR1-
GFP mice results in a GFP-labeling of microglia[13]. In YFP-H mouse line the YFP is expressed
under control of Thy1 promoter which leads to a sparse labeling of pyramidal neurons in cor-
tex and hippocampus [14]. Mice were housed in standard cages with food and water ad libitum.
The APP-PS1(dE9) line was crossed with CX3CR1-GFP. The resulting offspring [APP-PS1
(dE9)xCX3CR1+/-] was inbred to generate the [APP-PS1(dE9)xCX3CR1+/-], used for in vivo
imaging experiments. For control experiments (S1 Fig.) [APP-PS1(dE9)xCX3CR1+/-] x [APP-
PS1(dE9)xCX3CR1+/-] crossings resulted in [APP-PS1(dE9)xCX3CR1+/+], [APP-PS1(dE9)
xCX3CR1+/-] and [APP-PS1(dE9)xCX3CR1-/-]. Furthermore APP-PS1(dE9) was crossed to
the YFP-H line resulting in [APP-PS1(dE9)xYFP-H] mice, which were inbred. Mice of mixed
gender were used for experiments at indicated age.
The studies were carried out in accordance with an animal protocol approved by the
Ludwig-Maximilians-University Munich and the government of Upper Bavaria (Az. 55.2–
1–54–2531–188–09). The cranial window preparation and in vivo imaging were performed
under anesthesia, and all efforts were made to minimize suffering of the animals.
Immunohistochemistry
Briefly, mice anesthetized with an intraperitoneal injection of ketamine/xylazine (0.14 mg
ketamine / 0.01 mg xylazine per gram body weight; WDT/Bayer Health Care) were transcar-
dially perfused with PBS and 4% PFA and brains were prepared. 100 μm thick sections were
cut from postfixed brains. Free-floating sections were permeabilized with 2% Triton X-100
overnight and blocked with 10% normal goat serum and BSA. Microglia were immunohisto-
chemically labeled using Iba1-antibody (Wako, 1:200; secondary antibody A-21244 by Invitro-
gen, 1:500). Fibrillar Aβ plaque staining was performed with 145 μMMethoxy-X04 (provided
by Prof. Boris Schmidt from TU Darmstadt, Germany) in PBS for 30 min and subsequently
washed with PBS. Slices of CX3CR1-/- and CX3CR1+/- mice were bleached before staining for
Iba-1 and Methoxy-X04. Fluorescence images were acquired with a confocal laser scanning mi-
croscope mounted on an inverted microscope support (LSM 510, Carl Zeiss). Images were ac-
quired 0.22 μm pixel size and frame distance of 2 μm using a 40x/1.3 DIC oil objective. Images
were aquired from cortical or hippocampal tissue. Image stacks were acquired spanning a total
depth of at least 10 μm above and 10 μm below each selected amyloid plaque.
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Cranial window preparation and in vivo two-photon microscopy
Mice were anesthetized with an intraperitoneal injection of ketamine/xylazine (0.14 mg
ketamine / 0.01 mg xylazine per gram body weight; WDT/Bayer Health Care). Additionally, a
single dosage of dexamethasone (6 μg/g body weight; Sigma) was intraperitoneally adminis-
tered immediately before surgery. Utilizing the open skull preparation a cranial window was
placed above the somatosensory cortex. For repositioning during repetitive imaging a small
metal bar, containing a hole for a screw, was glued next to the window. Directly after surgery
mice received subcutaneously a single analgesic treatment with carprophen (7.5 μg/g body
weight; Pfizer) and a single antibiotic treatment with cefotaxim (0.25 mg/g body weight;
Pharmore).
Two-photon in vivo imaging was started after a 3–4 week recovery period post-surgery, uti-
lizing a LSM 5MP setup (Carl Zeiss) equipped with a MaiTai laser (Spectra Physics) and a 20x
water-immersion objective (1.0 NA) (Carl Zeiss). For amyloid plaque staining, methoxy-X04
(0.4 to 2.4 mg/kg; provided by Prof. Boris Schmidt from TU Darmstadt, Germany) was intra-
peritoneally injected 24 hours before imaging ([15]). Methoxy-X04 is a derivate of Congo red,
that specifically binds to amyloid deposits in post mortem tissue and in vivo and therefore pro-
vides a fluorescent label [15]. Mice were anesthetized by Isofluoran. Imaging sessions lasted for
no longer than 60 min and laser power was kept below 50 mW to avoid phototoxic effects. We
imaged up to three cortical positions with each position spanning 425 μm x 425 μm x 201 μm
in x-y-z (pixel distance in x/y: 0.42 μm; pixel distance in z: 3 μm). Care was taken to ensure
similar fluorescence levels in space and in time at every imaging session.
Data analysis
Analysis of confocal and multiphoton images was performed with unprocessed data. From
multiphoton imaging data only amyloid plaques were selected for analysis when at all imaging
sessions a total image stack with at least 10 μm above and 10 μm below the plaque was re-
corded. All interaction analysis of microglia with amyloid plaques was performed with 3D data
sets. For plaque volume determination, smallest and largest diameter of each plaque was mea-
sured from image projections using ZEN software (Zeiss). Assuming the plaque as a spheric el-
ement, the volume was calculated using the corresponding mean diameter. For illustration
purposes multiphoton images were deconvolved (AutoQuantX2, Media Cybernetics) and fil-
tered with an edge-preserving algorithm, followed by a local contrast change (Imaris 5.0.1, Bit-
plane). Confocal and multiphoton image stacks were aligned with Imaris 5.0.1, Bitplane.
Statistics: For histological ex vivo analysis a total of 188 small plaques from five animals
were identified (54/55/24/23/32). All images were analysed independently and identically. Two
photon in vivo imaging revealed a total of 21 new appearing plaques in four animals (2/4/9/6).
All time series data points were analysed independently and identically.
Results
On brain slices of 12-month-old APP-PS1(dE9) mice, microglia cells were immunohistologi-
cally stained and fibrillar amyloid deposits were labelled with Methoxy-XO4. Rarely, we ob-
served small amyloid plaques that were devoid of any detectable microglial contact (Fig. 1A);
in most cases, similar sized plaques were clearly contacted by microglia, partly exhibiting an
activated appearance (Fig. 1B). To characterize the relationship between plaque size and micro-
glial activation, we specifically imaged small amyloid plaques (which are supposed to corre-
spond to novel plaques) in cortex or hippocampus. Therefore, plaques with a diameter of up to
~10 μm (equates a volume of 524 μm3) were chosen randomly, while the microglia channel
was not visible to the investigator. Image-stacks were recorded by confocal microscopy
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covering the total plaque volume with additional 10 μm beneath and above each plaque. Subse-
quently, the microglial status around the plaque was classified into five levels: (0) Amyloid pla-
que devoid of any detectable microglial contact; (1) Amyloid plaque contacted by a single
surveying microglial process; (2) Amyloid plaque surrounded by various microglial processes;
Fig 1. Activation of microglia by small amyloid plaques.On brain slices of 12-month- old APP-PS1(dE9)
mice microglial cells were immunohistochemically labelled for Iba1 (green) and amyloid plaques were stained
with Methoxy-X04 (red). Small amyloid plaques were imaged and classified according to the microglial status.
A Image projections of an amyloid plaque lacking any microglial contact (level 0) at three magnifications.
Below, the single x-y-planes clarifying that no microglial process touches the plaque.B Exemplary images of
the stages of plaque-associated microglial (MG) activation (level 1 to level 4). The upper lower magnification
illustrates the microglial environment around the plaque, the higher magnification below highlights the
individual plaque. Notice that, although each plaque has a similar size, microglial reaction is diverse. C Small
plaques were classified according to their microglial activation level and plotted against the plaque volume.D
The number of microglial cells associated to the individual plaques was plotted against the plaque volume.
(The brains of five animals were analysed with a total of 188 small plaques. Red bars showmean with
standard deviation.)
doi:10.1371/journal.pone.0119768.g001
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(3) Amyloid plaque enclosed by activated (explicitly swollen) microglial processes; (4) Amyloid
plaque insulated from neuropil by activated microglial cell bodies (Fig. 1A-B). Whereas level 3
and level 4 exhibit distinct morphological signs of microglia activation, at level 2 the microglia
start to recognize and orientate toward the plaque. At level 0 and level 1, shape and number of
microglia processes at and nearby the amyloid plaque are indistinguishable from plaque-free
brain areas. It should be noted that all plaques shown in Fig. 1 A-B are of comparable size.
Hereunder, we will refer to activated microglia cells based on their morphological appearance
(level 3 and level 4).
In total, 188 small amyloid plaques were investigated from the brains of five animals. Six
very small plaques (volume between 0.9 and 33.5 μm3) were lacking any microglial detectable
contact (level 0) (Fig. 1C). An additional 32 plaques were classified as level 1, with volumes
reaching up to 168.3 μm3 while 40 plaques were classified as level 2 (volume between 3.6 and
143.8 μm3). About 50% of small amyloid plaques were associated with clear morphological
signs of microglia activation (level 3 and 4; Fig. 1C). The recruitment and activation of micro-
glial cells correlate weakly with plaque size (R2 = 0.1040). For example 73% of plaques in level 3
are smaller than 100 μm3, 12% are even smaller than 20 μm3. Analyzing the number of micro-
glia, we found that most small amyloid plaques were associated with only one microglial cell
(Fig. 1D). Only a very tiny quantity of small plaques were surrounded by three or four micro-
glia, with the volume of these plaques ranging from 37.4 μm3 to 434.9 μm3 (Fig. 1D). These re-
sults indicate that small plaques present a variable recruitment and activation of microglial
cells around them.
To confirm the ex vivo data and explore the dynamic of microglia activation by amyloid pla-
que formation we utilized in vivo two-photon microscopy. Therefore, we crossbred APP-PS1
(dE9) mice with CX3CR1 heterozygous knockout mice, which carry the EGFP gene at the
CX3CR1 locus providing a specific fluorescent labelling of microglia in the brain. Although
previous studies have shown an effect of heterozygous and homozygous knockout of CX3CR1
on amyloid plaque burden in Alzheimer-transgenic mice ([16]; [17]), in our hands plaque den-
sity, plaque area, plaque size and microglia area were indistinguishable in cortex and hippo-
campus of APP-PS1(dE9) and APP-PS1(dE9)xCX3CR1+/- (S1 Fig.).
Starting at an age of six months we repetitively imaged superficial volumes in the somato-
sensory and the primary motor cortex of APP-PS1(dE9)xCX3CR1+/- mice to scan for newborn,
Methoxy-X04 labelled amyloid plaques. To distinguish very small plaques from autofluores-
cent spots we recorded additionally to the Methoxy-X04 emission (short pass 485 nm) nonspe-
cific emission at 590–650 nm (S2 Fig.). New amyloid plaques were identified as Methoxy-X04
specifically-labelled structures that remained in place and typically grew in size over time
(S3 Fig.). In four mice, we were able to detect 21 new appearing plaques in total and followed
the microglial reaction on these plaques for up to 106 days (Fig. 2A). Interestingly, at the imag-
ing time-point of first appearance out of the 21 new appearing plaques we could not observe a
single plaques without any detectable microglial contact (level 0) (Fig. 2B). Except for one pla-
que, at the first detection time point all plaques were classified as level 1 or level 2, lacking clear
signs of microglial activation. Over time, most plaques induced a more serious morphological
activation of microglia, typically terminating at level 4. Nevertheless, the time point when
microglial activation was reached differed for individual plaques, ranging for level 4 between 7
and 42 days after first detection (Fig. 2B). Similarly, the plaque volume for microglial activation
was different, with the smallest plaque inducing level 4 at a size of 10.3 μm3 and the largest at a
size of 104.8 μm3 (Fig. 2C). There was no correlation between plaque volume and plaque life-
time at the time point, when microglial activation level 3 as well as level 4 was reached
(Fig. 2D). Occasionally we also observed a deactivation of microglia from a high level to a
lower one (Fig. 2A-C). Together these results suggest that the formation of individual amyloid
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plaques precedes the activation of microgial cells. Furthermore, the recruitment of microglia
does not seem to be directly dependent on the lifetime or the initial size of the corresponding
plaque. Although, eventually, all amyloid plaques are surrounded by activated microglial cells
(level 3–4), there is substantial variability between individual plaques before reaching this level.
Fig 2. In vivomonitoring of amyloid plaque inducedmicroglial activation. In the cortex of PS1(dE9)
xCX3CR1+/- mice, individual new appearing plaques (red, Methoxy-X04 stained) and the subsequent
microglia activation (green) were followed using two-photon microscopy. A Time series of image projections
of a newly formed plaque (starting with day 1) and the corresponding microglial reaction. The upper row
indicates the microglial environment, the lower row shows the plaque in higher magnification. Notice, at day 1
a microglial process is already contacting the plaque (level 1). At day 9 this plaque was classified as level 3
and level 4 was reached at day 29. Interestingly, at day 88 the plaque is mainly liberated from enclosing
microglia, which at day 92 is reverted to level 4 again. B Time dependent development of microglial activation
level for each plaque (colour coded) beginning with the time point of appearance. The box plots below
indicate the distribution of initial time points when microglia activation was reached (level 3 and 4). C Size
dependent development of microglial activation for individual plaques (colour coded). The box plots below
indicate the distribution of initial volume when microglia activation was reached (level 3 and 4). D No
correlation between plaque lifetime and plaque volume when microglial activation level 3 or 4 are reached.
doi:10.1371/journal.pone.0119768.g002
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Discussion
In the brain of AD patients, the amyloid burden is accompanied by clustering of activated
microglia around these amyloid plaques. The role of microglia in this pathology is
controversial. Hypotheses range from clearance of Aβ-aggregates to potential negative in-
flammatory effects and neuron elimination mediated by microglia ([18]; [19]; [20]). In
this descriptive study, but the first of its kind, we aimed to analyse the initiation of microglial
interaction with amyloid plaques in APP-PS1(dE9) transgenic mouse line. For very small
plaques we distinguished five levels of increasing interaction in brain slices, four of which
could be confirmed by in vivo two-photon microscopy. We observed that the degree of
microglia reaction showed a great variation with regards to size as well as lifetime of individu-
al small plaques.
In a more detailed description, we therefore herewith confirm the original finding by
Meyer-Luehmann and colleagues that the formation of amyloid plaques precedes the recruit-
ment of microglia ([21]). Typically, the plaque is touched by fine microglial processes before
swollen processes and finally activated microglial cell bodies envelope the whole plaque. How-
ever by the data it cannot be ruled out, that microglia might be involved in the formation of
plaques by releasing certain factors into the microenvironment.
An important question is whether the amyloid deposit itself is sensed by the microglia and
induces the subsequent microglial reactions. It has been shown that fibrillar Aβ can directly ac-
tivate microglia IL-1 expression ([22]). Nonetheless, it is not clear why the here observed reac-
tion of microglia to the individual small plaques is so diverse. After emergence of a plaque, we
observed that the morphological activation of microglia takes between 7–42 days to start. The
variation in initiation sizes and initiation time points after plaque formation of unequivocal
microglial activation supports the hypothesis that secondary consequences of amyloid deposi-
tion lead to the recruitment of microglia. This view is further supported by the fact that indeed
sporadically small plaques without any detectable association to microglia have been found.
One possible explanation could be that a developing amyloid plaque directly injures at some
time point its surrounding neuropil, and the subsequent release of neuron-derived signalling
molecules induces the recruitment of nearby microglial cells. Accordingly, neuritic dystrophies
which accompany the development of amyloid plaques might represent the site of acute neuro-
nal tissue damage (S4 Fig.). The different degree of neuropil alteration around a plaque over
time could explain the different levels of microglial activation, but at a certain point all plaques
are surrounded by activated microglia. However, we cannot rule out that neuronal injury
might also be a consequence of microglia activation. Although the microglia in humans might
respond differently to fibrillar Aβ, in AD brains microglial activation has been shown to prog-
ress with the neuropathological stage of the disease as well as with the progression of individual
amyloid plaques ([23], [24]). About one fifth of early, non-fibrillar amyloid plaques in AD
brains were found not to be associated with microglia, again questioning whether Aβ aggre-
gates per se can recruit these cells ([23]). Interestingly, the late-stage dense core plaques showed
less microglial association, paralleled by a reduced number of dystrophic neurites ([23]). Pre-
sumably, at this final stage the immediate vicinity of the plaque lacks neuronal tissue that can
be damaged.
In summary, we have provided a detailed description of the initial interaction of microglia
with newly developing amyloid plaques in an AD mouse model. Our results indicate that the
appearance of plaques alone might not be the direct cause of microglia recruitment. Alterna-
tively, the progressive tissue alteration around the plaques might be related to the microglia ac-
tivation. Clearly, the trigger which actually attracts the microglia to the amyloid lesion remains
to be identified.
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Supporting Information
S1 Fig. Amyloid plaque deposition is comparable in APP-PS1(dE9)x xCX3CR1+/+
and APP-PS1(dE9)xCX3CR1+/-. Coronal brain sections of 12 months APP-PS1(dE9)
xCX3CR1+/+(which are in fact APP-PS1(dE9)), APP-PS1(dE9)xCX3CR1+/- and APP-PS1
(dE9)xCX3CR1-/- were bleached and posteriorly immunohistochemically stained for micro-
glia (Iba-1, green), amyloid plaques were labelled with Methoxy-X04 (blue). There was no sig-
nificant difference in plaque density, plaque area, plaque size distribution or microglia area
between CX3CR1+/+ and CX3CR1+/- Alzheimer-transgenic animals in cortex and hippocam-
pus. (We analysed 5 CX3CR1+/+-mice and 6 CX3CR1+/—mice with 5 sections per animal.
Error bars indicate SEM.) Because of breading problems we were able to generate only one
APP-PS1(dE9)xCX3CR1-/—mouse, which we separately included into the graphs with dashed
lines. Although statistically not testable, plaque burden in this mouse seems to be highly re-
duced by the CX3CR1-knockout. Data analysis was performed using Imaris 5.0.1, Bitplane.
Surface rendering was performed for the various fluorescent channels resulting in the corre-
sponding plaque or microglia area. Plaque density was determined by fluorescent
spot detection.
(TIF)
S2 Fig. Detection of auto-fluorescent spots. Two-photon excitation of Methoxy-X04 labelled
amyloid plaques was performed at 750 nm and the signal was detected using a short pass (SP)
485 nm filter. To exclude false positive fluorescent spots from analysis, we recorded additional-
ly emission at 590–650 nm. These auto-fluorescent spots were found in the neuropil, but also
within microglial cells.
(TIF)
S3 Fig. Growth of newborn plaques (A) The change in plaque volume was followed over the
imaging period for each amyloid plaque analysed for microglia activation (Fig. 2). To compare
plaques the volume was normalized to 1 for the time point of first appearance. (B) To estimate
the growth rate data points of approximately weekly distance (+/- 1 day) were combined and
plotted over 5 weeks. The slope of linear regression is 0.575 which results in a weekly growth
rate of 4.025. (Error bars show SEM.)
(TIF)
S4 Fig. Amyloid plaques cause neuritic damage. In vivomicroscopic time series of image
projections of a new appearing plaque (A) and a preexisting plaque (B) stained with Methoxy-
X04 in a APP-PS1(dE9)xYFP-H mouse. In YFP-H mice the fluorescent reporter YFP is ex-
pressed under control of a Thy-1 promotor providing to sparse labelling of neurons. While de-
veloping the new (A) as well as the preexisting (B) plaque cause damage of the neuropil,
exemplarily apparent as neuritic swellings around the plaques. Notice that in B the neuritic pa-
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